BlackRock Institutional Trust’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock Institutional Trust’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$372K	Hold	213,649	–	–	﹤0.01%	3503
2016 Q3	$709K	Sell	213,649 -3	-0%	-$11	﹤0.01%	3400
2016 Q2	$919K	Sell	213,652 -99,293	-32%	-$449K	﹤0.01%	3335
2016 Q1	$1.76M	Sell	312,945 -6,183	-2%	-$80.3K	﹤0.01%	3091
2015 Q4	$5.49M	Buy	319,128 +38,098	+14%	+$908K	﹤0.01%	2673
2015 Q3	$5.93M	Sell	281,030 -9,318	-3%	-$319K	﹤0.01%	2622
2015 Q2	$14.4M	Sell	290,348 -29,662	-9%	-$1.77M	﹤0.01%	2151
2015 Q1	$25.1M	Buy	320,010 +2,138	+0.7%	+$133K	﹤0.01%	1798
2014 Q4	$19.3M	Sell	317,872 -25,157	-7%	-$1.26M	﹤0.01%	1937
2014 Q3	$14.6M	Buy	343,029 +27,749	+9%	+$1.49M	﹤0.01%	2083
2014 Q2	$19.5M	Buy	315,280 +17,477	+6%	+$1.02M	﹤0.01%	1978
2014 Q1	$19.4M	Buy	297,803 +14,590	+5%	+$987K	﹤0.01%	1984
2013 Q4	$15.9M	Buy	283,213 +7,224	+3%	+$406K	﹤0.01%	2108
2013 Q3	$16.9M	Buy	275,989 +10,081	+4%	+$683K	﹤0.01%	1988
2013 Q2	$15.5M	Buy	+265,908	New	+$16.4M	﹤0.01%	2007

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

BlackRock Institutional Trust's OREX Position: Q4 2016 in Review

BlackRock Institutional Trust held its Orexigen Therapeutics, Inc. (OREX) position steady in Q4 2016 at 213,649 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #3503.

BlackRock Institutional Trust first reported a position in OREX in Q2 2013 and has held it in 15 quarters since. The position peaked at $25.1M in Q1 2015. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

BlackRock Institutional Trust held 213,649 shares of Orexigen Therapeutics, Inc. worth $372K as of Q4 2016.
BlackRock Institutional Trust left its Orexigen Therapeutics, Inc. share count unchanged in Q4 2016.
Orexigen Therapeutics, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3503 holding.
BlackRock Institutional Trust first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Orexigen Therapeutics, Inc. position peaked at $25.1M in Q1 2015.
53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.